Drug Trial Radar · NCT02274233
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
Last checked: Nov 19, 2026Latest source record: Sep 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Oct 2014
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Sideris PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess safety and amount of the study drug in the blood after increasing doses of SP-420. The study will be conducted in patients with β-thalassemia.
Conditions
- Iron Overload
- Beta-Thalassemia
Interventions
SP-420Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Up to 35 days
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Sideris Investigative Site
Boston, Massachusetts
Sideris Investigative Site
New York, New York
Sideris Investigative Site
Philadelphia, Pennsylvania
Sideris Investigative Site
Toronto, Ontario, Canada
Sideris Investigative Site
Beirut, Lebanon
Sideris Investigative Site
Bangkok, Thailand
Sideris Investigative Site
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.